PURPOSE: Oxaliplatin-5-fluorouracil combinations have increased responses in first-line therapy up to 40% in advanced colorectal cancer. Unfortunately, those patients who will respond are unknown and initially sensitive patients become rapidly resistant to current therapies. FAS (CD95) and FAS ligand (FASL; CD95L) have been implicated in chemosensitivity through leading to apoptosis in response to DNA-damaging drugs. Whereas the proapoptotic role of FAS and FASL is well characterized, the function of their soluble forms as predictors of chemosensitivity remains unknown. PATIENTS AND METHODS: Blood samples were obtained from 68 patients with advanced colorectal cancer who received oxaliplatin-5-fluorouracil combinations in first-line therapy. Computed tomographic scans were done every 3 months and responses were evaluated by Response Evaluation Criteria in Solid Tumors criteria. ELISA soluble FAS and soluble FASL analysis were done before treatment and every 3 months until disease progression. Ratios between soluble FAS and soluble FASL were established and its values and variations through time were related to treatment responses. RESULTS: We found a significant increase in soluble FAS levels and a significant decrease in FASL at 3 months compared with baseline (13.2 versus 10.02 ng/mL; P=0.0001; 0.07 versus 0.14 ng/mL; P=0.007, respectively). A significant increase in the soluble FASL levels up to 9 months (fourth to fifth extractions; 0.26 ng/mL) of therapy compared with first to third extractions (0.11 ng/mL; P=0.003) was also found. A random effect regression statistical model determined that >1.2-fold increase in soluble FAS/soluble FASL ratio was a marker of chemosensitivity (P = 0.001). CONCLUSIONS: These data strongly indicate that an increment of soluble FAS/soluble FASL ratio after treatment could be an excellent marker of chemosensitivity in colorectal cancer. On the other hand, a decreased ratio after treatment can be a predictor of chemoresistance despite an initial response.
PURPOSE:Oxaliplatin-5-fluorouracil combinations have increased responses in first-line therapy up to 40% in advanced colorectal cancer. Unfortunately, those patients who will respond are unknown and initially sensitive patients become rapidly resistant to current therapies. FAS (CD95) and FAS ligand (FASL; CD95L) have been implicated in chemosensitivity through leading to apoptosis in response to DNA-damaging drugs. Whereas the proapoptotic role of FAS and FASL is well characterized, the function of their soluble forms as predictors of chemosensitivity remains unknown. PATIENTS AND METHODS: Blood samples were obtained from 68 patients with advanced colorectal cancer who received oxaliplatin-5-fluorouracil combinations in first-line therapy. Computed tomographic scans were done every 3 months and responses were evaluated by Response Evaluation Criteria in Solid Tumors criteria. ELISA soluble FAS and soluble FASL analysis were done before treatment and every 3 months until disease progression. Ratios between soluble FAS and soluble FASL were established and its values and variations through time were related to treatment responses. RESULTS: We found a significant increase in soluble FAS levels and a significant decrease in FASL at 3 months compared with baseline (13.2 versus 10.02 ng/mL; P=0.0001; 0.07 versus 0.14 ng/mL; P=0.007, respectively). A significant increase in the soluble FASL levels up to 9 months (fourth to fifth extractions; 0.26 ng/mL) of therapy compared with first to third extractions (0.11 ng/mL; P=0.003) was also found. A random effect regression statistical model determined that >1.2-fold increase in soluble FAS/soluble FASL ratio was a marker of chemosensitivity (P = 0.001). CONCLUSIONS: These data strongly indicate that an increment of soluble FAS/soluble FASL ratio after treatment could be an excellent marker of chemosensitivity in colorectal cancer. On the other hand, a decreased ratio after treatment can be a predictor of chemoresistance despite an initial response.
Authors: Jordi Codony-Servat; Xabier Garcia-Albeniz; Carles Pericay; Vicente Alonso; Pilar Escudero; Carlos Fernández-Martos; Rosa Gallego; Anna Martínez-Cardús; Eva Martinez-Balibrea; Joan Maurel Journal: Med Oncol Date: 2013-01-22 Impact factor: 3.064
Authors: Wei Xiao; Mohammed L Ibrahim; Priscilla S Redd; John D Klement; Chunwan Lu; Dafeng Yang; Natasha M Savage; Kebin Liu Journal: Mol Cancer Res Date: 2018-11-14 Impact factor: 5.852
Authors: Ramazan Yildiz; Mustafa Benekli; Suleyman Buyukberber; Ali Osman Kaya; Banu Ozturk; Emel Yaman; Veli Berk; Ugur Coskun; Deniz Yamac; Banu Sancak; Aytug Uner Journal: J Cancer Res Clin Oncol Date: 2010-02-13 Impact factor: 4.553
Authors: Marco Ragusa; Giuseppe Avola; Rosario Angelica; Davide Barbagallo; Maria Rosa Guglielmino; Laura R Duro; Alessandra Majorana; Luisa Statello; Loredana Salito; Carla Consoli; Maria Grazia Camuglia; Cinzia Di Pietro; Giuseppe Milone; Michele Purrello Journal: BMC Cancer Date: 2010-07-19 Impact factor: 4.430
Authors: Fee Klupp; Lena Neumann; Christoph Kahlert; Johannes Diers; Niels Halama; Clemens Franz; Thomas Schmidt; Moritz Koch; Juergen Weitz; Martin Schneider; Alexis Ulrich Journal: BMC Cancer Date: 2016-07-18 Impact factor: 4.430